Signifor

Chemical Namepasereotide
Dosage FormInjection (subcutaneous; 0.3 mg/mL, 0.6 mg/mL, 0.9 mg/mL)
Drug ClassAnalogs
SystemEndocrine
CompanyNovartis
Approval Year2012

Indication

  • For the treatment of patients with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option
  • For the treatment of patients with Cushing’s disease for whom pituitary surgery is not an option or has not been curative
Last updated on 4/22/2022

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Signifor (pasereotide) Prescribing Information.2012Novartis Pharmaceuticals Corporation, East Hanover, NJ